Published in Cancer Biother Radiopharm on August 01, 2008
The promyelocytic leukemia zinc finger protein: two decades of molecular oncology. Front Oncol (2012) 1.03
Expression and Function of Kruppel Like-Factors (KLF) in Carcinogenesis. Curr Genomics (2009) 1.01
Tissue prognostic biomarkers in primary cutaneous melanoma. Virchows Arch (2014) 0.96
Smooth muscle α-actin is a direct target of PLZF: effects on the cytoskeleton and on susceptibility to oncogenic transformation. Oncotarget (2010) 0.88
A nine-gene signature predicting clinical outcome in cutaneous melanoma. J Cancer Res Clin Oncol (2012) 0.84
Loss of PLZF expression in prostate cancer by immunohistochemistry correlates with tumor aggressiveness and metastasis. PLoS One (2015) 0.81
An attempt at a molecular prediction of metastasis in patients with primary cutaneous melanoma. PLoS One (2012) 0.79
ZBTB16: a novel sensitive and specific biomarker for yolk sac tumor. Mod Pathol (2016) 0.78
Revisiting determinants of prognosis in cutaneous melanoma. Cancer (2015) 0.77
Genome-wide screen identifies a novel prognostic signature for breast cancer survival. Oncotarget (2017) 0.75
Underexpression of Specific Interferon Genes Is Associated with Poor Prognosis of Melanoma. PLoS One (2017) 0.75
Gab2-mediated signaling promotes melanoma metastasis. Am J Pathol (2009) 1.21
Management of lower lid ectropion. Dermatol Surg (2006) 1.01
Soft x-ray therapy for cutaneous basal cell and squamous cell carcinomas. J Am Acad Dermatol (2005) 0.98
Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer (2002) 0.91
Short German guidelines: basal cell carcinoma. J Dtsch Dermatol Ges (2008) 0.91
Peripheral blood neutrophils as independent immunologic predictor of response and long-term survival upon immunotherapy in metastatic renal-cell carcinoma. Cancer Biother Radiopharm (2008) 0.85
Soft tissue reconstruction of the nose. Facial Plast Surg (2011) 0.85
One-stage reconstruction of nasal defects: evaluation of the use of modified auricular composite grafts. Facial Plast Surg (2011) 0.84
Predictive impact of retinoid X receptor-alpha-expression in renal-cell carcinoma. Cancer Biother Radiopharm (2004) 0.84
Dose-dependent treatment benefit in high-risk melanoma patients receiving adjuvant high-dose interferon alfa-2b. Cancer Biother Radiopharm (2005) 0.84
GM-CSF plus antigenic peptide vaccination in locally advanced melanoma patients. Cancer Biother Radiopharm (2007) 0.80
Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients. Cancer Chemother Pharmacol (2007) 0.77
Long-term maintenance therapy in interferon-alpha2a/interleukin-2-pretreated advanced renal-cell carcinoma patients. Cancer Biother Radiopharm (2006) 0.76
Metastatic renal carcinoma long-term survivors treated with s.c. interferon-alpha and s.c. interleukin-2. Cancer Biother Radiopharm (2005) 0.76
Increased level of circulating U2 small nuclear RNA fragments indicates metastasis in melanoma patients. Clin Chem Lab Med (2015) 0.75
[Radiotherapy of basal cell carcinoma]. J Dtsch Dermatol Ges (2006) 0.75
Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan. Am J Clin Oncol (2011) 0.75
[Brief guidelines: Basal cell carcinoma of the skin]. J Dtsch Dermatol Ges (2006) 0.75
Individualized synthetic peptide vaccines with GM-CSF in locally advanced melanoma patients. Cancer Biother Radiopharm (2004) 0.75
Fractional polynomials in a new metastatic renal carcinoma continuous prognostic index involving histology, laboratory, and clinical predictors. Cancer Biother Radiopharm (2007) 0.75
Primary mucosal malignant melanoma of the head and neck. Facial Plast Surg (2011) 0.75
Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients. Cancer Chemother Pharmacol (2009) 0.75
Surgical reconstruction of eyelids. Facial Plast Surg (2011) 0.75